DOCSLIB.ORG

Teva Pharmaceutical Industries Ltd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Teva Pharmaceutical Industries Ltd m n a d v s g o PRODUCT v1 2015 CATALOGUE h p b e q f i t w c l r z www.tapi.com PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF ABIRATERONE a ACYCLOVIR x x x AFATINIB ALCLOMETASONE DIPROPIONATE x x ALENDRONATE SODIUM x x x ALLOPURINOL x x x x AMCINONIDE x x x AMITRIPTYLINE HCL x x x x x AMLODIPINE BESYLATE x x x ANASTROZOLE x x x ANIDULAFUNGIN APIXABAN APREMILAST ARIPIPRAZOLE x x ARIPIPRAZOLE LAUROXIL ATORVASTATIN CALCIUM* x x x x ATOSIBAN ACETATE ATRACURIUM BESYLATE x x x AZACITIDINE x x AZITHROMYCIN x x x x AZTREONAM x BECLOMETHASONE DIPROPIONATE x x x x b BETAMETHASONE ACETATE x x x BETAMETHASONE BASE x x x BETAMETHASONE DIPROPIONATE x x x x BETAMETHASONE VALERATE x x x x BICALUTAMIDE x x BIMATOPROST x x BIVALIRUDIN x x BLEOMYCIN SULFATE x x BORTEZOMIB x x x * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF BROMOCRIPTINE MESYLATE x x b BUDESONIDE x x x x BUPRENORPHINE BASE x x BUPRENORPHINE HCL x x x BUTORPHANOL TARTRATE x x CABAZITAXEL x CABERGOLINE x x x x c CALCIPOTRIENE (CALCIPOTRIOL)* x x x CALCITRIOL x x x CANDESARTAN CILEXETIL x CAPECITABINE x x CARBIDOPA x x x x CARBOPLATIN x x x x CARFILZOMIB CARVEDILOL BASE x x x x x CARVEDILOL PHOSPHATE x CASPOFUNGIN ACETATE x x CERITINIB CHLORMADINONE ACETATE x x CICLOSPORIN x x x x x CILOSTAZOL x x x x CINACALCET HCL x x CISATRACURIUM BESYLATE x x CISPLATIN x x x CLARITHROMYCIN x x x x x CLOBETASOL PROPIONATE x x x x x CLONAZEPAM x CLOPIDOGREL BISULFATE x x x x CYPROTERONE ACETATE x x d DABIGATRAN ETEXILATE x DARIFENACIN HBR x x * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF DASATINIB x d DAUNORUBICIN HCL x x x DEFERASIROX x x DEFEROXAMINE MESYLATE x x x DESLORATADINE x x DESMOPRESSIN ACETATE x x x x DESONIDE x x DESOXYCORTICOSTERONE (DESOXYCORTONE) PIVALATE x DESVENLAFAXINE BASE x x DESVENLAFAXINE FUMARATE x DESVENLAFAXINE SUCCINATE x DEXAMETHASONE -17 VALERATE DIFLORASONE DIACETATE x x x DIFLUPREDNATE x x x DIHYDRO-ALPHA-ERGOCRYPTINE MESILATE DIHYDROERGOCRISTINE MESILATE x DIHYDROERGOTAMINE MESILATE x x DIHYDROERGOTOXINE MESILATE x x x x DILTIAZEM HCL x x x DIMETHYL FUMARATE DOCETAXEL x x x DOLUTEGRAVIR DONEPEZIL HCL x x x DORZOLAMIDE HCL x x DOXEPIN HCL x x x DOXERCALCIFEROL x DOXORUBICIN HCL x x x DROSPIRENONE x x x x DULOXETINE HCL x x x e EDOXABAN ELDECALCITOL * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF ELETRIPTAN HBR x x e EMPAGLIFLOZIN EPIRUBICIN HCL x x x x x EPTIFIBATIDE x x ERGOMETRINE (ERGONOVINE) MALEATE x x x x ERGOTAMINE TARTRATE x x x x ERLOTINIB HCL x x x ESZOPICLONE x x ETODOLAC x x x x ETOPOSIDE x x x x EXENATIDE x x x EZETIMIBE x x x FAMCICLOVIR x x FEBUXOSTAT f FIDAXOMICIN FINGOLIMOD FLUDARABINE PHOSPHATE x x x FLUDROCORTISONE ACETATE x x FLUNISOLIDE x x FLUOCINOLONE ACETONIDE x x x FLUOCINONIDE x x x FLUOROMETHOLONE ACETATE x x FLUOROMETHOLONE BASE x x FLUOROURACIL x x x FLUOXETINE HCL x x x x FLUTICASONE FUROATE FLUTICASONE PROPIONATE x x x x FLUVASTATIN SODIUM x x x FLUVOXAMINE MALEATE x x FORMOTEROL FUMARATE x x FULVESTRANT * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF FUROSEMIDE x x x f GABAPENTIN* x x x x x GALANTAMINE HBR x x x GEMCITABINE HCL* x x x x g GEMFIBROZIL x x x HALOPERIDOL x x x HALOPERIDOL DECANOATE x x HYDROCHLOROTHIAZIDE x x h IBANDRONATE SODIUM x x x IBRUTINIB ICATIBANT i IDARUBICIN HCL x x IMATINIB MESYLATE x x x x IMIPRAMINE HCL x x IMIQUIMOD x x x INGENOL IRBESARTAN* x x x x IRINOTECAN HCL x x x LAMOTRIGINE x x l LANSOPRAZOLE x x x x x LATANOPROST x x LEDIPASVIR LEFLUNOMIDE x x LETROZOLE x x LEUPROLIDE (LEUPRORELIN ACETATE) x x x LEVETIRACETAM x x x x LEVODOPA* x x x LEVOFLOXACIN x x x LEVOSALBUTAMOL HCL (LEVALBUTEROL) x x LINACLOTIDE LINAGLIPTIN * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF LINEZOLID l LIRAGLUTIDE LIXISENATIDE LOPERAMIDE HCL x x x LOSARTAN POTASSIUM* x x x x x LOVASTATIN x x x LURASIDONE MACITENTAN m MAXACALCITOL MEDROXYPROGESTERONE ACETATE x x x x MEGESTROL ACETATE x x x MEMANTINE HCL x x METHYLDOPA* x x x METHYLERGONOVINE MALEATE x x METHYLPREDNISOLONE HEMISUCCINATE x x METHYLPREDNISOLONE SODIUM SUCCINATE x x METOPROLOL SUCCINATE x x x METOPROLOL TARTRATE x x x MIRTAZAPINE x x x MITOMYCIN x x x MOMETASONE FUROATE x x x x MONTELUKAST SODIUM x x MUPIROCIN x x x MUPIROCIN CALCIUM x x x MYCOPHENOLATE MOFETIL x x x MYCOPHENOLATE SODIUM x NAPROXEN x x x x NAPROXEN SODIUM x x x NATEGLINIDE x x x n NEFAZODONE HCL x NICERGOLINE x x * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF NIFEDIPINE x x x n NILOTINIB HCL x NORGESTIMATE x x OCTREOTIDE ACETATE x x x o OLANZAPINE x x OLMESARTAN MEDOXOMIL x x x OMEPRAZOLE x x x ONDANSETRON BASE x x ONDANSETRON HCL x x x x x OXALIPLATIN x x x x PACLITAXEL x x x x x p PALIPERIDONE x x PALONOSETRON HCL* x PAMIDRONIC ACID x x x PANCURONIUM BROMIDE x x PANTOPRAZOLE SODIUM x x x PARICALCITOL x x x PAROXETINE HCL x x x PEMETREXED* PENTOXIFYLLINE x x PERAMPANEL PERGOLIDE MESYLATE x x x PIOGLITAZONE HCL x x x PRAMLINTIDE ACETATE PRAVASTATIN SODIUM x x x x x PREGABALIN x x x q PROBENECID x x QUETIAPINE FUMARATE x x x RALOXIFENE HCL x r RALTEGRAVIR FREE ACID RALTEGRAVIR POTASSIUM * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF RAMELTEON x r REGORAFENIB RILPIVIRINE RISEDRONATE SODIUM x x x RISPERIDONE x x x x x RIVAROXABAN ROCURONIUM BROMIDE x x x ROMIDEPSIN ROSUVASTATIN CALCIUM* x x x ROTIGOTINE SALBUTAMOL (ALBUTEROL) x x s SALBUTAMOL (ALBUTEROL) SULFATE x x x SAXAGLIPTIN SILDENAFIL CITRATE x x SILVER SULFADIAZINE x x SILYMARIN x x SIMVASTATIN x x x x x SITAGLIPTIN MALATE x SITAGLIPTIN PHOSPHATE x SOFOSBUVIR SOLIFENACIN SUCCINATE x x x SORAFENIB BESYLATE SUNITINIB TACROLIMUS x x x x t TADALAFIL x x x TAMOXIFEN CITRATE x x x TELMISARTAN x x x TERAZOSIN HCL x x x TERGURIDE x TERIPARATIDE ACETATE TICAGRELOR * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF TICLOPIDINE HCL x x x t TIGECYCLINE x x TIMOLOL MALEATE TIOTROPIUM BROMIDE x x TOBRAMYCIN x x x x TOLTERODINE TARTRATE x x TORASEMIDE x x TRAVOPROST x x TRAZODONE HCL x TRIAMCINOLONE x x TRIAMCINOLONE ACETONIDE x x x x x TRIPTORELIN PAMOATE u ULIPRISTAL ACETATE UMECLIDINIUM BROMIDE VALACICLOVIR HCL x x x v VALSARTAN* x x x x VECURONIUM BROMIDE x x VENLAFAXINE HCL x x x VILANTEROL TRIFENATE w VILAZODONE WARFARIN SODIUM CLATHRATE x ZALEPLON x x z ZOLEDRONIC ACID x x x ZOLMITRIPTAN x x ZOLPIDEM TARTRATE x x x * TAPI can provide several different polymorphs or processes of this product.
Load more

Recommended publications
  • 30 Day Change Notice Effective Date
    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • INTEGRIS Formulary July 2017
    INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T
    [Show full text]
  • Printed Formulary Catalog Basic
    Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Index B Alphabetical List of Pharmaceutical Product Names
    INDEX B ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES PRODUCT NAME Page PRODUCT NAME Page 292 97 ACYCLOVIR 17 3TC (EDS) 14 ACYCLOVIR 17 5-AMINOSALICYLIC ACID (MESALAMINE) 170 " 18 ABACAVIR SO4 13 ADALAT XL 57 ABACAVIR SO4/LAMIVUDINE 13 ADALIMUMAB 220 ABACAVIR SO4/LAMIVUDINE/ZIDOVUDINE 13 ADAPALENE 206 ABATACEPT 220 ADCIRCA (EDS) 89 ABILIFY (EDS) 123 ADEFOVIR DIPIVOXIL 18 ACARBOSE 187 ADHESIVE WIPES (EDS) 239 ACCEL PIOGLITAZONE (EDS) 190 ADVAGRAF (EDS) 231 ACCEL TOPIRAMATE 112 ADVAIR (EDS) 33 ACCEL-CITALOPRAM 114 ADVAIR DISKUS (EDS) 33 ACCOLATE (EDS) 232 AGGRENOX (EDS) 87 ACCU-CHEK 1 MINI (EDS) 238 AGRYLIN 221 ACCU-CHEK 2 MINI (EDS) 238 AIROMIR 32 ACCU-CHEK ADVANTAGE 142 ALCOHOL PREP 234 ACCU-CHEK AVIVA 142 ALCOHOL SWAB 234 ACCU-CHEK COMPACT 142 ALDACTAZIDE-25 82 ACCU-CHEK FASTCLIX MOBILE 234 ALDACTAZIDE-50 82 ACCU-CHEK LINKASSIST (EDS) 239 ALDACTONE 148 ACCU-CHEK MOBILE 142 ALDARA (EDS) 209 ACCU-CHEK MULTICLIX 234 ALENDRONATE (EDS) 220 ACCU-CHEK RAPID D (EDS) 236 ALENDRONATE SODIUM 220 " 237 ALENDRONATE SODIUM (EDS) 220 " 238 ALENDRONATE SODIUM/VITAMIN D3 ACCU-CHEK SPIRIT (EDS) 236 (CHOLECALCIFEROL) 220 ACCU-CHEK TENDER 1 (EDS) 238 ALERTEC (EDS) 133 " 239 ALESSE 181 ACCU-CHEK TENDER 2 (EDS) 238 ALFACALCIDOL 217 " 239 ALFUZOSIN 220 ACCU-CHEK ULTRAFLEX 1 (EDS) 237 ALGLUCOSIDASE ALFA 221 " 238 ALLOPURINOL 221 ACCU-CHEK ULTRAFLEX 2 (EDS) 237 ALMOTRIPTAN MALATE 33 " 238 ALOMIDE 158 ACCUPRIL 79 ALPHAGAN 157 ACCURETIC 80 ALPHAGAN P 157 ACCUTANE 209 ALPRAZOLAM 134 ACCUTREND 142 ALPRAZOLAM 134 ACEBUTOLOL 48 ALTACE 80 ACEBUTOLOL HCL 48 " 81
    [Show full text]
  • Pharmacokinetics of Ophthalmic Corticosteroids
    British Journal ofOphthalmology 1992; 76: 681-684 681 MINI REVIEW Br J Ophthalmol: first published as 10.1136/bjo.76.11.681 on 1 November 1992. Downloaded from Pharmacokinetics of ophthalmic corticosteroids Corticosteroids have been used by ophthalmologists with an identical vehicle, the aqueous humour concentrations of increasing frequency over the past 30 years, with the these steroids are almost identical.'9 None the less it is concomitant development of a diverse range of drop, essential when considering such empirical data, to recall that ointment, subconjunctival, and oral preparations. Though the systemic anti-inflammatory effect of both betamethasone the clinical benefits and side effects of such corticosteroid and dexamethasone is five to seven times that of predniso- preparations have been well documented, their basic lone.39"' The local anti-inflammatory potency of ocular pharmacokinetics in the human eye have yet to be fully steroids has yet to be fully investigated and whilst early work established. Indeed most of our pharmacokinetic knowledge suggested that prednisolone acetate 1% had the greatest anti- of these drugs has been elucidated by extrapolation of data inflammatory effect in experimental keratitis,'7 later studies obtained from rabbit experiments.1-26 These results can be demonstrated that fluorometholone acetate in a 1% formu- significantly disparate from human data because of the lation was equally efficacious in the same model.26 However, thinner rabbit cornea, lower rabbit blink rate, effect of prednisolone
    [Show full text]
  • Compositions Comprising Nebivolol
    (19) TZZ ZZ__T (11) EP 2 808 015 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.12.2014 Bulletin 2014/49 A61K 31/34 (2006.01) A61K 31/502 (2006.01) A61K 31/353 (2006.01) A61P 9/00 (2006.01) (21) Application number: 14002458.9 (22) Date of filing: 16.11.2005 (84) Designated Contracting States: • O’Donnell, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Morgantown, WV 26505 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Bottini, Peter Bruce SK TR Morgantown, WV 26505 (US) • Mason, Preston (30) Priority: 31.05.2005 US 141235 Morgantown, WV 26504 (US) 10.11.2005 US 272562 • Shaw, Andrew Preston 15.11.2005 US 273992 Morgantown, WV 26504 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Samson & Partner accordance with Art. 76 EPC: Widenmayerstraße 5 09015249.7 / 2 174 658 80538 München (DE) 05848185.4 / 1 890 691 Remarks: (71) Applicant: MYLAN LABORATORIES, INC This application was filed on 16-07-2014 as a Morgantown, NV 26504 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Davis, Eric Morgantown, WV 26508 (US) (54) Compositions comprising nebivolol (57) The active ingredients of the pharmaceutical composition described consist of nebivolol, one or more ACE inhibitors and one or more ARB. EP 2 808 015 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 808 015 A1 Description [0001] This application is a continuation-in-part of application Ser.
    [Show full text]
  • Fb45953c - 5/15
    2015 Three Tier Formulary Reference Guide A list of medications that may lower your patients’ costs TABLE OF CONTENTS INTRODUCTION . ii Product Selection Criteria . ii Member Copayment Contributions . ii Pharmacy and Therapeutics (P&T) Committee . iii Generic Substitution . iii DESI Drugs . iv Legend . iv Prior Authorization (PA) . v Prior Authorization Drug List . v Drugs with Quantity Limitations (QL) . vi Step Therapy (ST) . vii Drugs with Step Therapy . vii Specialty Pharmacy Products . viii Excluded Drugs - Alternatives . x 2015 Preventive Drug List . xi Affordable Care Act Requirements . xiii Editor's Note . xiv Pharmacy Appeals . xiv Notice . xiv Clinical References . xv THERAPEUTIC CHAPTER INDEX . .1 BLUECROSS BLUESHIELD OF TENNESSEE THREE TIER FORMULARY . .4 INDEX . .58 i INTRODUCTION BlueCross BlueShield of Tennessee is pleased to provide a Three Tier Formulary. This formulary was reviewed and approved by the BlueCross Pharmacy and Therapeutics (P&T) Committee and can assist practitioners in selecting drugs for members whose drug benefits are administered through BlueCross BlueShield of Tennessee. Product Selection Criteria The BlueCross P&T Committee considers U.S. Food and Drug Administration (FDA) approved drugs for inclusion in the formulary. The evaluation includes a literature review, and expert opinion may be sought. Formal reviews are prepared and typically address the following information: • Effectiveness • Contraindications • Safety • Pharmacokinetics • Comparison studies • Patient administration/compliance considerations • Approved indications • Medical outcome and pharmacoeconomic studies • Adverse effects • Cost When a new drug is considered for formulary inclusion, an attempt will be made to examine the drug relative to similar drugs currently on formulary. Drugs reviewed by the P&T Committee are typically assigned to either Tier 2 or Tier 3, considering cost and clinical usefulness of the product.
    [Show full text]
  • Therapeutic Drug Class
    EFFECTIVE Version Department of Vermont Health Access Updated: 02/16/17 Pharmacy Benefit Management Program /2016 Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria) The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include: "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives" From Act 127 passed in 2002 The following pages contain: • The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories. • The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent. • Within both of these categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters. Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non- preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization. GHS/Change Healthcare GHS/Change Healthcare GHS/Change Healthcare Sr. Account Manager: PRESCRIBER Call Center: PHARMACY Call Center: PA Requests PA Requests Michael Ouellette, RPh Tel: 1-844-679-5363; Fax: 1-844-679-5366 Tel: 1-844-679-5362 Tel: 802-922-9614 Note: Fax requests are responded to within 24 hrs.
    [Show full text]
  • Commentary—1St Supplement to Usp30 - Nf25
    COMMENTARY—1ST SUPPLEMENT TO USP30 - NF25 Revision proposals published in Pharmacopeial Forum often elicit public comments that are forwarded to the appropriate Expert Committee for review and response. Some revision proposals can advance to official status with necessary modifications without requiring further public review. In such cases a summary of comments received and the Expert Committee's responses are published in the Commentary section of USP website at the time the revision becomes official. For those proposals that require further revision and republication in Pharmacopeial Forum, a summary of the comments and the Committee's responses will be included in the briefing that accompanies the publication. The Commentary section is not part of the official text of the monograph and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis for the Expert Committee's response to public comments. If there is a difference between the contents of the Commentary section and the official monograph, the text of the official monograph prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary section, shall prevail. Where appropriate, the Commentary includes a separate discussion of proposals related to international harmonization of the USP, the European Pharmacopoeia, and the Japanese Pharmacopoeia in order to highlight such proposals. The Commentary is presented in the following order: USP Monographs, Dietary Supplement Monographs, General Chapters, NF Monographs. USP MONOGRAPHS Monograph/Section: Allopurinol/Multiple sections Expert Committee: MD-GRE No. of Commenters: 2 Comment summary #1: Commenter suggested that a proposal for Related compounds, previously submitted by the commenter and published in PF 28(5), be reconsidered by the Committee.
    [Show full text]
  • Prior Authorization PDL Implementation Schedule
    Prior Authorization PDL Implementation Schedule Effective Date: Item January 1, 2017 – Descriptive Therapeutic Class Drugs on PDL Drugs which Require PA Nbr Updated: March 1, 2018 1 ADD/ADHD Amphetamine Salt Combo Tablet ( Generic Adderall®) Amphetamine ODT (Adzenys® XR ODT) Stimulants and Related Agents Amphetamine Salt Combo ER (Adderall XR®) Amphetamine Suspension (Dyanavel XR®) Atomoxetine Capsule (Strattera®) Amphetamine Salt Combo ER (Generic; Authorized Generic for Adderall XR) Dexmethylphenidate (Generic; Authorized Generic of Focalin®) Amphetamine Sulfate Tablet (Evekeo®) Dexmethylphenidate ER (Focalin XR®) Armodafinil Tablet (Generic; Authorized Generic; Nuvigil®) Dextroamphetamine Solution (Procentra®) Clonidine ER Tablet (Generic; Kapvay®) Dextroamphetamine Sulfate Tablet (Generic) Dexmethylphenidate (Focalin®) Guanfacine ER Tablet (Generic) Dexmethylphenidate XR (Generic; Authorized Generic for Focalin XR) Lisdexamfetamine Capsule (Vyvanse®) Dextroamphetamine Sulfate Capsule ER (Generic; Dexedrine®Spansule) Methylphenidate IR (Generic) Dextroamphetamine IR Tablet (Zenzedi®) Methylphenidate ER Chew (Quillichew ER®) Dextroamphetamine Solution (Generic for Procentra®) Methylphenidate ER Capsule (Metadate CD®) Guanfacine ER Tablet (Intuniv®) Methylphenidate ER Tablet (Generic; Generic Concerta®; Methamphetamine (Generic; Desoxyn®) Authorized Generic Concerta®) Methylphenidate ER Susp (Quillivant XR®) Methylphenidate IR (Ritalin®) Modafinil Tablet (Generic) Methylphenidate Solution (Generic; Authorized Generic; Methylin®) Methylphenidate
    [Show full text]